Equities Analysts Offer Predictions for AQST FY2027 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – HC Wainwright issued their FY2027 EPS estimates for shares of Aquestive Therapeutics in a research report issued on Monday, March 9th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.52) for the year. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Wednesday, March 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The business had revenue of $13.02 million for the quarter, compared to analyst estimates of $13.28 million.

A number of other research firms have also recently commented on AQST. Lake Street Capital set a $6.00 price target on Aquestive Therapeutics in a research note on Tuesday, February 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Aquestive Therapeutics has a consensus rating of “Buy” and a consensus target price of $8.80.

Aquestive Therapeutics Stock Performance

NASDAQ:AQST opened at $4.20 on Tuesday. The company’s 50-day simple moving average is $4.13 and its 200-day simple moving average is $5.22. Aquestive Therapeutics has a fifty-two week low of $2.12 and a fifty-two week high of $7.55. The stock has a market capitalization of $512.57 million, a P/E ratio of -5.38 and a beta of 1.61.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC increased its position in shares of Aquestive Therapeutics by 12.2% in the first quarter. AQR Capital Management LLC now owns 129,019 shares of the company’s stock valued at $374,000 after buying an additional 14,025 shares in the last quarter. Bank of Montreal Can raised its holdings in Aquestive Therapeutics by 31.1% in the 2nd quarter. Bank of Montreal Can now owns 20,052 shares of the company’s stock valued at $66,000 after acquiring an additional 4,752 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Aquestive Therapeutics by 16.2% in the second quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company’s stock valued at $6,545,000 after purchasing an additional 276,295 shares during the last quarter. Creative Planning raised its holdings in shares of Aquestive Therapeutics by 15.3% during the 2nd quarter. Creative Planning now owns 98,751 shares of the company’s stock worth $327,000 after acquiring an additional 13,130 shares during the period. Finally, Intech Investment Management LLC raised its stake in Aquestive Therapeutics by 30.1% during the second quarter. Intech Investment Management LLC now owns 54,393 shares of the company’s stock worth $180,000 after purchasing an additional 12,600 shares during the period. Institutional investors and hedge funds own 32.45% of the company’s stock.

Key Stories Impacting Aquestive Therapeutics

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Grant to retain CMO could help preserve leadership continuity (minor positive/neutral for execution). Aquestive Inducement Award
• Neutral Sentiment: Reported short‑interest data in the feeds appears inconsistent/zero and is likely not meaningful; ignore until exchanges confirm reliable figures (no linked source).
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs in a securities class action covering purchases from June 16, 2025 to Jan 8, 2026, and are seeking lead plaintiffs — this creates legal risk, potential litigation costs, and investor uncertainty. Example notice from Rosen Law Firm. Rosen Law Firm Notice
• Negative Sentiment: Additional plaintiff‑solicitation notices from other firms (Faruqi & Faruqi; The Gross Law Firm; Bernstein Liebhard; Robbins LLP) reinforce the class‑action overhang and may accelerate selling by holders seeking to avoid litigation exposure. (Representative links: Faruqi & Faruqi and The Gross Law Firm.) Faruqi & Faruqi Notice Gross Law Firm Notice
• Negative Sentiment: Standalone investor alert coverage (TMCNet) flags alleged misrepresentations by management and encourages lead‑plaintiff motions — such media/legal attention typically increases volatility and selling pressure. TMCNet Investor Alert
• Negative Sentiment: HC Wainwright lowered FY2027 EPS expectations (analyst R. Selvaraju now sees ~$0.52 loss vs. consensus ~0.46 loss), compounding investor concern after the company’s March quarter EPS miss — analyst downgrades and earnings shortfalls are selling catalysts. HC Wainwright / Market Data

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.